Definitive Contract HHSN272201600011C

This federal contract award, HHSN272201600011C, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the University of Massachusetts Medical School (UMMS) for "STAGED VACCINE DEVELOPMENT". The $17,298,573.00 cost-no-fee contract does not have a set-aside designation. Under this contract, UMMS serves as the prime contractor and has subcontracted a portion of the work to the University of Wisconsin System. The contract is focused on refining and implementing a product development plan for the scaled-up cGMP production of recombinant gp120 protein vaccines in CHO cells for a potential Phase II clinical study. This contract award is part of NIAID's Staged Vaccine Development program, which supports the advancement of promising vaccine candidates through various stages of development.